Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
Georg Pfeiler,Dominik Hlauschek,Erica L. Mayer,Christine Deutschmann,Stephanie Kacerovsky-Strobl,Miguel Martin,Jane Lowe Meisel,Nicholas Zdenkowski,Sibylle Loibl,Marija Balic,Haeseong Park,Aleix Prat,Claudine Isaacs,Emilio Bajetta,Justin M. Balko,Merixtell Bellet-Ezquerra,Judith Bliss,Harold Burstein,Fatima Cardoso,Hannes Fohler,Theodoros Foukakis,Karen A. Gelmon,Matthew Goetz,Tufia C. Haddad,Hiroji Iwata,Jacek Jassem,Soo-Chin Lee,Barbro Linderholm,Maartje Los,Eleftherios P. Mamounas,Kathy D. Miller,Patrick G. Morris,Elisabetta Munzone,Einav Nili Gal-Yam,Alistair Ring,Lois Shepherd,Christian Singer,Christoph Thomssen,Ling-Ming Tseng,Pinuccia Valagussa,Eric P. Winer,Antonio C. Wolff,Gabriele Zoppoli,Jana Machacek-Link,Celine Schurmans,Xin Huang,Eric Gauthier,Christian Fesl,Amylou C. Dueck,Angela DeMichele,Michael Gnant,David Cameron,Sarra El-Abed,Hope S. Rugo,Guenther G. Steger,Tiffany Traina,Gustavo Werutsky,Norman Wolmark,on behalf of the PALLAS Groups and Investigators
DOI: https://doi.org/10.1200/JCO.23.00126
IF: 45.3
2023-08-11
Journal of Clinical Oncology
Abstract:PURPOSE BMI affects breast cancer risk and prognosis. In contrast to cytotoxic chemotherapy, CDK4/6 inhibitors are given at a fixed dose, irrespective of BMI or weight. This preplanned analysis of the global randomized PALLAS trial investigates the impact of BMI on the side-effect profile, treatment adherence, and efficacy of palbociclib. METHODS Patients were categorized at baseline according to WHO BMI categories. Neutropenia rates were assessed with univariable and multivariable logistic regression. Time to early discontinuation of palbociclib was analyzed with Fine and Gray competing risk models. Unstratified Cox models were used to investigate the association between BMI category and time to invasive disease-free survival (iDFS). 95% CIs were derived. RESULTS Of 5,698 patients included in this analysis, 68 (1.2%) were underweight, 2,082 (36.5%) normal weight, 1,818 (31.9%) overweight, and 1,730 (30.4%) obese at baseline. In the palbociclib arm, higher BMI was associated with a significant decrease in neutropenia (unadjusted odds ratio for 1-unit change, 0.93; 95% CI, 0.91 to 0.94; adjusted for age, race ethnicity, region, chemotherapy use, and Eastern Cooperative Oncology Group at baseline, 0.93; 95% CI, 0.92 to 0.95). This translated into a significant decrease in treatment discontinuation rate with higher BMI (adjusted hazard ratio [HR] for 10-unit change, 0.75; 95% CI, 0.67 to 0.83). There was no significant improvement in iDFS with the addition of palbociclib to ET in any weight category (normal weight HR, 0.84; 95% CI, 0.63 to 1.12; overweight HR, 1.10; 95% CI, 0.82 to 1.49; and obese HR, 0.95; 95% CI, 0.69 to 1.30) in this analysis early in follow-up (31 months). CONCLUSION This preplanned analysis of the PALLAS trial demonstrates a significant impact of BMI on side effects, dose reductions, early treatment discontinuation, and relative dose intensity. Additional long-term follow-up will further evaluate whether BMI ultimately affects outcome.
oncology